State Street Corp Tiziana Life Sciences LTD Transaction History

State Street Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.51 - $1.1 $10,481 - $22,607	20,552 Added 8.41%	265,000 $288,000
Q4 2022 Feb 14, 2023	BUY	$0.56 - $0.78 $14,833 - $20,660	26,488 Added 12.15%	244,448 $146,000
Q3 2022 Nov 15, 2022	SELL	$0.55 - $0.83 $57,443 - $86,686	-104,442 Reduced 32.39%	217,960 $170,000
Q2 2022 Aug 15, 2022	BUY	$0.66 - $1.06 $2,385 - $3,830	3,614 Added 1.13%	322,402 $240,000
Q1 2022 May 16, 2022	BUY	$0.62 - $1.25 $12,895 - $25,998	20,799 Added 6.98%	318,788 $335,000
Q4 2021 Feb 14, 2022	BUY	$0.89 - $1.66 $265,210 - $494,661	297,989 New	297,989 $286,000

1.03M

19.2K

Ticker TLSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,273,000
Market Cap $91M
Description
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, m...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.